EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Recombinant factor IX Fc for the treatment of hemophilia B

Rolf Ljung iD, Davide Matino iD, Amy D Shapiro iD

European Journal of Haematology · 2024-05 · 112 (5) · 678-691

DOI: 10.1111/ejh.14176 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 18.02.2024. Verfasst von Rolf Ljung und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences-Pediatrics, Lund University, Lund, Sweden. Hauptthemen laut MEDLINE: Factor IX, Hemophilia B. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sobi, Sanofi, Swedish Orphan Biovitrum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current hemophilia B treatment guidelines recommend routine prophylaxis with factor IX (FIX) replacement products, tailored to maintain plasma activity at levels that will prevent bleeds. However, plasma FIX activity may not be the primary determinant or best indicator of hemostatic efficacy due to its extravascular distribution. FIX replacement therapy has evolved to include extended half‐life (EHL) products that provide effective bleed protection when administered at intervals of 7 days or longer. rFIXFc is a recombinant fusion protein with an extended circulation time. rFIXFc has a biodistribution profile consistent with distribution into extravascular space, where it may support hemostasis at sites of vessel injury independent of circulating plasma activity levels. The safety and efficacy of rFIXFc prophylaxis is well established in adults, adolescents and children including previously untreated patients with hemophilia B, with substantial evidence from clinical trials and real‐world clinical practice. This review describes the pharmacokinetic characteristics of rFIXFc, summarizes available safety and efficacy data, and evaluates the use of rFIXFc in special populations. Current hemophilia B treatment challenges, including target FIX plasma levels, perioperative use, and management of patients with comorbidities, are discussed together with the potential role of EHL products in the future treatment landscape of hemophilia B.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor IXHemophilia BAdultChildAdolescentHumansTissue DistributionHemorrhageRecombinant Fusion ProteinsHalf-Life

Stichwörter der Autor:innen

blood coagulation factorsfactor IX deficiencyhemophilia Bhemostasispharmacokinetics

Substanzen

Factor IXRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Clinical Sciences-Pediatrics, Lund University, Lund, Sweden.
  • Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Indiana Hemophilia & Thrombosis Center, Inc, Indianapolis, Indiana, USA.

ORCID-Profile: Rolf Ljung, Davide Matino, Amy D Shapiro

Förderung

  • Sobi
  • Sanofi
  • Swedish Orphan Biovitrum

Zitieren

APA

Ljung, R., Matino, D., & Shapiro, A. D. (2024). Recombinant factor IX Fc for the treatment of hemophilia B. European Journal of Haematology, 112(5), 678-691. https://doi.org/10.1111/ejh.14176

Vancouver

Ljung R, Matino D, Shapiro AD. Recombinant factor IX Fc for the treatment of hemophilia B. European Journal of Haematology. 2024;112(5):678-691. doi:10.1111/ejh.14176

BibTeX
@article{Ljung2024,
  author = {Ljung, Rolf and Matino, Davide and Shapiro, Amy D},
  title = {Recombinant factor IX Fc for the treatment of hemophilia B},
  journal = {European Journal of Haematology},
  year = {2024},
  volume = {112},
  number = {5},
  pages = {678--691},
  doi = {10.1111/ejh.14176}
}
Kostenlos starten →